Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

Completed · Phase 1/Phase 2

Conditions studied: Carcinoma, Renal Cell, Metastases, Neoplasm

In brief

This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.

Key facts

Study ID

NCT00056173

Run by

Aptose Biosciences Inc.

People needed

43

Starts

2002-03-01

Last updated by the study team

2008-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Bay Area Cancer Research Group — Concord, California, United States
• USC-Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• CA Hematology Oncology Medical Group — Torrance, California, United States
• Innovative Medical Research of South Florida, Inc. — Miami Shores, Florida, United States
• University of Chicago Medical Center — Chicago, Illinois, United States
• Ochsner Clinic Foundation — New Orleans, Louisiana, United States
• SUNY Upstate Medical University — Syracuse, New York, United States
• Comprehensive Cancer Center of Wake Forest University — Winston-Salem, North Carolina, United States
• The Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.